Can Antagonist Protocol be the Protocol of Choice in in Vitro Fertilization Patients?
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- number of oocytes collected and fertilized
Study Overview
Brief Summary
The antagonist protocol in a novel method of stimulation in the in vitro fertilization (IVF) patients. It has been tried in poor responders, polycystic ovary (PCO) patients and normal females undergoing IVF. Can it be used with the same efficacy in all patients?
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 44 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •age: 20- 44 years
- •Poor responder females according to Bologna criteria
- •Polycystic ovarian disease females according to Rotterdam criteria
- •Females with infertility causes other than poor responders, or PCO; male factor or tubal block
Exclusion Criteria
- •refusal to get enrolled in the study
- •cases of infertility due to severe male factor
Arms & Interventions
Normal
Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
Intervention: Gonadotropins releasing hormone antagonist (Drug)
Poor responders
Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
Intervention: Gonadotropins releasing hormone antagonist (Drug)
Polycystic ovarian disease
Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
Intervention: Gonadotropins releasing hormone antagonist (Drug)
Outcomes
Primary Outcomes
number of oocytes collected and fertilized
Time Frame: 6 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Dina Mohamed Refaat Dakhly
lecturer of obstetrics and gynecology
Woman's Health University Hospital, Egypt